India's indigenous solution to COVID-19 in progress

▴ India's indigenous solution to COVID-19 in progress
Monoclonal antibody leads for COVID-19: A way forward In combating COVID-19

To fight the Novel coronavirus SARS-COV-2, the virus behind the worldwide outbreak of COVID-19 disease, a Nagpur based Indian biotechnology company, GeNext Genomics, is contributing by isolating the antibody gene pool of the cured COVID-19 patients that will unravel target antibodies for neutralizing SARS-COV-2. The therapeutic antibody is a bullet-like drug which targets and neutralizes the virus. One of the core biological characteristics of SARS-CoV-2 is the presence of spike proteins that enable this virus to invade host cells through its receptor binding domain (RBD) and cause infection. RBD is a crucial region on the virus's spike protein which is being evaluated for identifying inhibitory/neutralizing molecules. The GNG team isolated the antibodies from a diverse gene pool which were phage displayed and panned through RBD and spike proteins of SARS-COV-2.

Using its proprietary Antibody Library Platform, GNG has successfully identified a few strong binders that will soon be evaluated for its efficacy towards target and developing a potential future therapy. Currently, the team is characterizing these binders for neutralization and efficacy against SARS-COV-2. The development would go in phase-wise manner with collaboration for pre-clinical and clinical studies. GNG hence aims to build a therapeutic monoclonal antibody neutralizing RBD domain.

Speaking on the development Supriya Kashikar, Founder & CEO, GeNext Genomics said "GNG is working towards developing an indigenous solution to COVID-19 by identifying Monoclonal Antibody Binders from cured Patients of COVID-19". She further added that "Monoclonal Antibody has a huge potential in formulating a biologic drug for SARS-COV-2." She also added that, "Our Prime Minister addressed the scientific fraternity to work towards this pandemic and that has triggered us to use our expertise and try to bring out the solution. This is just the first milestone but we will fast track it to successful lead development."

Currently, monoclonal antibody-based therapy for COVID-19 has been approved by FDA for emergency. GeNext Genomics aims to build a therapeutic valued antibody which will be much efficacious than current approved therapy. Although drug discovery is a long journey, the scientists at GNG aim to complete the molecule validation and antibody development by early 2021.

Apart from COVID-19 therapeutic target validation, GNG is also developing Biosimilar Clone of Golimumab under National Biopharma Mission. GNG aims to develop a therapeutic pipeline gradually and make India self-sustained with its discovery and solutions for healthcare.

Tags : #GeNextGenomics #LatestNewsonGeNextGenomics19thNov #LatestPharmaNews19thNov #SolutiontoCOVID-19 #LatestNewsonCOVIDTreatment19thNov #FightAgainstCorona #USFDA #India #Nagpur

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

The Surprising Link Between Sleep and Age Perception: What You Need to KnowMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
The Dark Side of Beauty: Kidney Damage from Hair Straightening TreatmentsMarch 29, 2024
Avance Clinical at World Vaccine Congress to Share Latest Vaccine Clinical Trial News Including an HIV-1 StudyMarch 29, 2024
Sexual wellness superstore, Love Depot launches digital campaign to deliver every desireMarch 28, 2024
Recharge Your Life: Simple Ways to Boost Your Physical and Mental EnergyMarch 28, 2024
The Neurological Toll of Common Household Chemicals: Insights from Recent ResearchMarch 28, 2024
The Aging Puzzle: Decoding the Mechanisms of AgingMarch 28, 2024
The Double-Edged Sword of Kala-azar Treatment: Shedding Light on Eye ComplicationsMarch 28, 2024
FTCCI Launches Industry-Academia Connect to improve the employability of Engineering Graduates and address the growing demand for Talent in Emerging TechMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy SystemMarch 27, 2024
2nd Edition of IIFL JITO Ahimsa Run for peace & for non-violence to be held on 31st MarchMarch 27, 2024
Brij Hotels Announced 4 Million in Series A Funding March 27, 2024
Combatting Childhood Sedentariness: The Key to Preventing Premature Vascular DamageMarch 27, 2024
Crucial Findings: Unlocking Paths to Combat Ebola's DevastationMarch 27, 2024
Guarding Against Disease: The Crucial Role of Oral Hygiene in Preventive HealthcareMarch 27, 2024
Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in IndiaMarch 26, 2024
Surmandal's Tribute to the Legends of Hindustani Classical MusicMarch 26, 2024
In Moscow, over 350,000 mammograms have been analyzed using artificial intelligence as part of the compulsory health insurance programMarch 26, 2024